An update on the potential role of intestinal first-pass metabolism for the prediction of drug–drug interactions: the role of PBPK modeling

The consequence of regional gradients of P-gp and CYP3A4 for drug-drug interactions by P-gp inhibitors and the P-gp/CYP3A4 interplay in the human intestine ex vivo

(2017) Ming Li et al.   TOXICOLOGY IN VITRO

An update on the role of intestinal cytochrome P450 enzymes in drug disposition

(2016) Fang Xie et al.   Acta Pharmaceutica Sinica B

Use of a Physiologically Based Pharmacokinetic Model for Quantitative Prediction of Drug–Drug Interactions via CYP3A4 and Estimation of the Intestinal Availability of CYP3A4 Substrates

(2015) Yoko Mano et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Proximal Roux-en-Y Gastric Bypass Alters Drug Absorption Pattern But Not Systemic Exposure of CYP3A4 and P-glycoprotein Substrates

(2015) Lingtak-Neander Chan et al.   PHARMACOTHERAPY

Diindolylmethane, a naturally occurring compound, induces CYP3A4 and MDR1 gene expression by activating human PXR

(2015) Satyanarayana R. Pondugula et al.   TOXICOLOGY LETTERS

A Physiologically Based Pharmacokinetic Model for Voriconazole Disposition Predicts Intestinal First-pass Metabolism in Children

(2014) Nicole R. Zane et al.   CLINICAL PHARMACOKINETICS

Effect of Standardized Cranberry Extract on the Activity and Expression of Selected Biotransformation Enzymes in Rat Liver and Intestine

(2014) Hana Bártíková et al.   MOLECULES

A Mechanistic Physiologically Based Pharmacokinetic-Enzyme Turnover Model Involving both Intestine and Liver to Predict CYP3A Induction-Mediated Drug–Drug Interactions

(2013) Haifang Guo et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Human cytochromes P450 in health and disease

(2013) D. W. Nebert et al.   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

Piperine activates human pregnane X receptor to induce the expression of cytochrome P450 3A4 and multidrug resistance protein 1

(2013) Yue-Ming Wang et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates – An evaluation and case study using GastroPlus™

(2012) Aki T. Heikkinen et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Cyclosporine Inhibition of Hepatic and Intestinal CYP3A4, Uptake and Efflux Transporters: Application of PBPK Modeling in the Assessment of Drug-Drug Interaction Potential

(2012) Michael Gertz et al.   PHARMACEUTICAL RESEARCH

Long-term effects of gastric bypass and duodenal switch on systemic exposure of atorvastatin

(2012) Gunn Signe Jakobsen et al.   SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES

Physiologically Based Pharmacokinetic Modeling of Intestinal First-Pass Metabolism of CYP3A Substrates with High Intestinal Extraction

(2011) M. Gertz et al.   DRUG METABOLISM AND DISPOSITION

Role of Intestinal Cytochrome P450 (P450) in Modulating the Bioavailability of Oral Lovastatin: Insights from Studies on the Intestinal Epithelium-Specific P450 Reductase Knockout Mouse

(2011) Y. Zhu et al.   DRUG METABOLISM AND DISPOSITION

In vitroandin vivosmall intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences

(2011) Hiroshi Komura et al.   DRUG METABOLISM REVIEWS

A Critical Analysis of the Interplay between Cytochrome P450 3A and P-Glycoprotein: Recent Insights from Knockout and Transgenic Mice

(2011) R. A. B. van Waterschoot et al.   PHARMACOLOGICAL REVIEWS

Significant Increase in Systemic Exposure of Atorvastatin After Biliopancreatic Diversion With Duodenal Switch

(2010) I B Skottheim et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data

(2010) M. Gertz et al.   DRUG METABOLISM AND DISPOSITION

Contribution of Intestinal Cytochrome P450-Mediated Metabolism to Drug-Drug Inhibition and Induction Interactions

(2010) Aleksandra Galetin et al.   Drug Metabolism and Pharmacokinetics

Cytochrome P450-mediated metabolism in the human gut wall

(2010) Kirstin Thelen et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Effect of Variations in the Amounts of P-Glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the Human Small Intestine on PBPK Models for Predicting Intestinal First Pass

(2010) Arnaud Bruyère et al.   MOLECULAR PHARMACEUTICS

Simulations of the Nonlinear Dose Dependence for Substrates of Influx and Efflux Transporters in the Human Intestine

(2009) Michael B. Bolger et al.   AAPS Journal

Mechanistic Approaches to Predicting Oral Drug Absorption

(2009) Weili Huang et al.   AAPS Journal

Population-Based Mechanistic Prediction of Oral Drug Absorption

(2009) Masoud Jamei et al.   AAPS Journal

Identification of Novel Substrates for Human Cytochrome P450 2J2

(2009) C. A. Lee et al.   DRUG METABOLISM AND DISPOSITION

Semiphysiologically Based Pharmacokinetic Models for the Inhibition of Midazolam Clearance by Diltiazem and Its Major Metabolite

(2009) X. Zhang et al.   DRUG METABOLISM AND DISPOSITION

Mini-series: I. Basic science. Uncertainty and inaccuracy of predicting CYP-mediated in vivo drug interactions in the ICU from in vitro models: focus on CYP3A4

(2009) Stéphane Mouly et al.   INTENSIVE CARE MEDICINE

Physiologically Based Predictions of the Impact of Inhibition of Intestinal and Hepatic Metabolism on Human Pharmacokinetics of CYP3A Substrates

(2009) Frederique Fenneteau et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

The Drug Transporter−Metabolism Alliance: Uncovering and Defining the Interplay

(2009) Leslie Z. Benet   MOLECULAR PHARMACEUTICS

Intestinal First-Pass Metabolism of CYP3A4 Substrates

(2008) Motohiro Kato   Drug Metabolism and Pharmacokinetics

Presystemic elimination of budesonide in man when administered locally at different levels in the gut, with and without local inhibition by ketoconazole

(2008) Janeric Seidegård et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES